Treatment of patients with systemic sclerosis with autologous regulatory Т-cells
Considering the fact that a decrease in the content and functional activity of T-reg plays an important role in the immunopathogenesis of many systemic diseases of the connective tissue, the use of a large amount of T-reg can have a therapeutic effect.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs
Standard treatment of Systemic Sclerosis according to the clinical protocols
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, Belarus
ACR/EULAR systemic sclerosis criteria
Сalculation of ACR/EULAR systemic sclerosis criteria score
Time frame: 6 month
ACR/EULAR systemic sclerosis criteria
Сalculation of ACR/EULAR systemic sclerosis criteria score
Time frame: 1 year
Adverse effects associated with the therapy
Determination of adverse effects associated with the therapy
Time frame: 1 month
Adverse effects associated with the therapy
Determination of adverse effects associated with the therapy
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.